000136810 001__ 136810
000136810 005__ 20240229105100.0
000136810 0247_ $$2doi$$a10.1002/1878-0261.12062
000136810 0247_ $$2pmid$$apmid:28388012
000136810 0247_ $$2pmc$$apmc:PMC6068350
000136810 0247_ $$2ISSN$$a1574-7891
000136810 0247_ $$2ISSN$$a1878-0261
000136810 0247_ $$2altmetric$$aaltmetric:18637252
000136810 037__ $$aDKFZ-2018-01248
000136810 041__ $$aeng
000136810 082__ $$a610
000136810 1001_ $$aSexton-Oates, Alexandra$$b0
000136810 245__ $$aMethylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence.
000136810 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2018
000136810 3367_ $$2DRIVER$$aarticle
000136810 3367_ $$2DataCite$$aOutput Types/Journal article
000136810 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660132102_23718
000136810 3367_ $$2BibTeX$$aARTICLE
000136810 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136810 3367_ $$00$$2EndNote$$aJournal Article
000136810 520__ $$aChildhood pilocytic astrocytomas (PA) are low-grade tumours with an excellent prognosis. However, a minority, particularly those in surgically inaccessible locations, have poorer long-term outcome. At present, it is unclear whether anatomical location in isolation, or in combination with underlying biological variation, determines clinical behaviour. Here, we have tested the utility of DNA methylation profiling to inform tumour biology and to predict behaviour in paediatric PA. Genome-wide DNA methylation profiles were generated for 117 paediatric PAs. Using a combination of analyses, we identified DNA methylation variants specific to tumour location and predictive of behaviour. Receiver-operating characteristic analysis was used to test the predictive utility of clinical and/or DNA methylation features to classify tumour behaviour at diagnosis. Unsupervised analysis distinguished three methylation clusters associated with tumour location (cortical, midline and infratentorial). Differential methylation of 5404 sites identified enrichment of genes involved in embryonic nervous system development. Specific hypermethylation of NEUROG1 and NR2E1 was identified as a feature of cortical tumours. A highly accurate method to classify tumours according to behaviour, which combined three clinical features (age, location and extent of resection) and methylation level at a single site, was identified. Our findings show location-specific epigenetic profiles for PAs, potentially reflecting their cell type of origin. This may account for differences in clinical behaviour according to location independent of histopathology. We also defined an accurate method to predict tumour behaviour at diagnosis. This warrants further testing in similar patient cohorts.
000136810 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000136810 588__ $$aDataset connected to CrossRef, PubMed,
000136810 7001_ $$aDodgshun, Andrew$$b1
000136810 7001_ $$0P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aHovestadt, Volker$$b2$$udkfz
000136810 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b3$$udkfz
000136810 7001_ $$aAshley, David M$$b4
000136810 7001_ $$aSullivan, Michael$$b5
000136810 7001_ $$aMacGregor, Duncan$$b6
000136810 7001_ $$aSaffery, Richard$$b7
000136810 773__ $$0PERI:(DE-600)2322586-5$$a10.1002/1878-0261.12062$$gVol. 12, no. 8, p. 1219 - 1232$$n8$$p1219 - 1232$$tMolecular oncology$$v12$$x1574-7891$$y2018
000136810 909CO $$ooai:inrepo02.dkfz.de:136810$$pVDB
000136810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136810 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000136810 9141_ $$y2018
000136810 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL ONCOL : 2015
000136810 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136810 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136810 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136810 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136810 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136810 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136810 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136810 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL ONCOL : 2015
000136810 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lB060 Molekulare Genetik$$x0
000136810 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000136810 980__ $$ajournal
000136810 980__ $$aVDB
000136810 980__ $$aI:(DE-He78)B060-20160331
000136810 980__ $$aI:(DE-He78)B062-20160331
000136810 980__ $$aUNRESTRICTED